WHO Adds Pfizer-BioNTech COVID-19 Vaccine Ready-to-Use Formulation to Emergency Use Authorization


WHO included in its emergency use authorization the new ready-to-use formulation of the Pfizer-BioNTech Comirnaty vaccine, which contains Tris/Sucrose and does not require dilution before administration.

This vaccine comes in packs of 10 or 195 vials, with a shelf life of six months when stored between -90°C and -60°C, and a shelf life of 10 weeks when stored between 2°C and 8°C within the six-month shelf life. For more information, visit:


  • Share: